Company Description
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products.
In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions.
Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services.
Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling.
The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies.
Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 18, 1997 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 192 |
| CEO | Shawn M. O'Connor |
Contact Details
Address: 42505 10th Street West Lancaster, California 93534-7059 United States | |
| Phone | 661-723-7723 |
| Website | simulations-plus.com |
Stock Details
| Ticker Symbol | SLP |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001023459 |
| CUSIP Number | 829214105 |
| ISIN Number | US8292141053 |
| Employer ID | 95-4595609 |
| SIC Code | 7373 |
Key Executives
| Name | Position |
|---|---|
| Dr. Walter S. Woltosz M.A.S., M.S. | Co-Founder and Chairman |
| Shawn M. O'Connor | Chief Executive Officer |
| William Frederick | Chief Operating Officer, Chief Financial Officer and Secretary |
| John Anthony DiBella M.S. | President of PBPK and Cheminformatics Solutions |
| Dr. Brett A. Howell Ph.D. | President of Quantitative Systems Pharmacology Solutions |
| Jill Fiedler-Kelly M.S. | President of Clinical Pharmacology and Pharmacometrics Services |
| Viera Lukacova Ph.D. | Chief Science Officer |
| Dr. Bud Nelson J.D., Ph.D. | Vice President of Corporate Counsel and Personal Data Protection Officer |
| Arlene Padron | Corporate Director of Marketing |
| Lindsay Luke | Executive Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 10-Q | Quarterly Report |
| Apr 3, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 144 | Filing |
| Mar 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 8-K | Current Report |
| Jan 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |